Symbols / KLDO $0.00 +0.00% Kaleido Biosciences, Inc.
KLDO Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2022-04-04 | down | Chardan Capital | Buy → Neutral | $2 |
| 2022-01-31 | main | Chardan Capital | — → Buy | $3 |
| 2021-11-12 | main | Chardan Capital | — → Buy | $11 |
| 2021-11-03 | main | JMP Securities | — → Market Outperform | $22 |
| 2021-10-19 | down | Morgan Stanley | Equal-Weight → Underweight | $3 |
| 2021-03-08 | main | Morgan Stanley | — → Equal-Weight | $12 |
| 2021-02-09 | init | Piper Sandler | — → Overweight | $19 |
| 2021-01-19 | main | Morgan Stanley | — → Equal-Weight | $13 |
| 2020-12-23 | init | JMP Securities | — → Outperform | $22 |
| 2020-08-10 | main | Morgan Stanley | — → Equal-Weight | $8 |
| 2020-07-15 | main | Morgan Stanley | — → Equal-Weight | $7 |
| 2020-05-21 | down | Morgan Stanley | Overweight → Equal-Weight | $8 |
| 2019-04-23 | init | Chardan Capital | — → Buy | $18 |
| 2019-03-25 | init | JP Morgan | — → Neutral | $15 |
| 2019-03-25 | init | Goldman Sachs | — → Buy | $20 |
| 2019-03-25 | init | Canaccord Genuity | — → Buy | $19 |
| 2019-03-25 | init | Morgan Stanley | — → Overweight | $17 |
- Kaleido Biosciences, Inc. (KLDO) Stock Price, News, Quote & History - Yahoo Finance Sun, 24 Feb 2019 09
- KLDO Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 01
- Kaleido Biosciences Stock Price Forecast. Should You Buy KLDO? - StockInvest.us hu, 10 Dec 2020 06
- StockWatch: Kaleido Shares Crater as Company Ceases Operations - Genetic Engineering and Biotechnology News Fri, 08 Apr 2022 07
- Friday's after hours session: top gainers and losers - ChartMill Fri, 18 Jun 2021 07
- First Tracks Biotherapeutics (TRAX) Stock Trends and Sentiment 2026 $TRAX - MarketBeat Mon, 01 Jun 2026 07
- These stocks are moving in today's after hours session - ChartMill Fri, 08 Apr 2022 07
- These stocks are gapping in today's session - ChartMill hu, 22 Jul 2021 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2021-12-31 |
|---|---|---|
| Total Revenue |
|
1.10
|
| Operating Revenue |
|
1.10
|
| Operating Expense |
|
88.77
|
| Research And Development |
|
67.80
|
| Selling General And Administration |
|
20.97
|
| General And Administrative Expense |
|
20.97
|
| Salaries And Wages |
|
10.96
|
| Other Gand A |
|
10.01
|
| Total Expenses |
|
88.77
|
| Operating Income |
|
-87.67
|
| Total Operating Income As Reported |
|
-87.67
|
| EBITDA |
|
-85.09
|
| Normalized EBITDA |
|
-85.09
|
| Reconciled Depreciation |
|
2.36
|
| EBIT |
|
-87.45
|
| Net Income |
|
-90.29
|
| Pretax Income |
|
-90.29
|
| Net Non Operating Interest Income Expense |
|
-2.77
|
| Interest Expense Non Operating |
|
2.84
|
| Net Interest Income |
|
-2.77
|
| Interest Expense |
|
2.84
|
| Interest Income Non Operating |
|
0.07
|
| Interest Income |
|
0.07
|
| Other Income Expense |
|
0.14
|
| Other Non Operating Income Expenses |
|
0.14
|
| Tax Rate For Calcs |
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-90.29
|
| Net Income From Continuing Operation Net Minority Interest |
|
-90.29
|
| Net Income From Continuing And Discontinued Operation |
|
-90.29
|
| Net Income Continuous Operations |
|
-90.29
|
| Normalized Income |
|
-90.29
|
| Net Income Common Stockholders |
|
-90.29
|
| Diluted NI Availto Com Stockholders |
|
-90.29
|
| Line Item | Trend | 2021-12-31 |
|---|---|---|
| Total Assets |
|
50.14
|
| Current Assets |
|
42.31
|
| Cash Cash Equivalents And Short Term Investments |
|
38.47
|
| Cash And Cash Equivalents |
|
38.47
|
| Prepaid Assets |
|
3.58
|
| Assets Held For Sale Current |
|
0.25
|
| Total Non Current Assets |
|
7.83
|
| Net PPE |
|
5.67
|
| Gross PPE |
|
11.14
|
| Accumulated Depreciation |
|
-5.47
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.59
|
| Construction In Progress |
|
0.19
|
| Other Properties |
|
7.44
|
| Leases |
|
1.92
|
| Other Non Current Assets |
|
2.16
|
| Total Liabilities Net Minority Interest |
|
39.53
|
| Current Liabilities |
|
29.68
|
| Payables And Accrued Expenses |
|
12.36
|
| Payables |
|
5.67
|
| Accounts Payable |
|
5.67
|
| Current Accrued Expenses |
|
6.69
|
| Current Debt And Capital Lease Obligation |
|
16.14
|
| Current Debt |
|
16.14
|
| Other Current Borrowings |
|
16.14
|
| Current Deferred Liabilities |
|
0.83
|
| Current Deferred Revenue |
|
0.83
|
| Other Current Liabilities |
|
0.35
|
| Total Non Current Liabilities Net Minority Interest |
|
9.85
|
| Long Term Debt And Capital Lease Obligation |
|
5.55
|
| Long Term Debt |
|
5.55
|
| Other Non Current Liabilities |
|
4.30
|
| Stockholders Equity |
|
10.61
|
| Common Stock Equity |
|
10.61
|
| Capital Stock |
|
0.04
|
| Common Stock |
|
0.04
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
42.60
|
| Ordinary Shares Number |
|
42.60
|
| Additional Paid In Capital |
|
375.03
|
| Retained Earnings |
|
-364.47
|
| Total Equity Gross Minority Interest |
|
10.61
|
| Total Capitalization |
|
16.16
|
| Working Capital |
|
12.63
|
| Invested Capital |
|
32.30
|
| Total Debt |
|
21.69
|
| Net Tangible Assets |
|
10.61
|
| Tangible Book Value |
|
10.61
|
| Interest Payable |
|
0.18
|
| Line Item | Trend | 2021-12-31 |
|---|---|---|
| Operating Cash Flow |
|
-77.09
|
| Cash Flow From Continuing Operating Activities |
|
-77.09
|
| Net Income From Continuing Operations |
|
-90.29
|
| Depreciation Amortization Depletion |
|
2.36
|
| Depreciation And Amortization |
|
2.36
|
| Other Non Cash Items |
|
0.89
|
| Stock Based Compensation |
|
10.34
|
| Operating Gains Losses |
|
-0.13
|
| Gain Loss On Sale Of PPE |
|
-0.13
|
| Change In Working Capital |
|
-0.26
|
| Change In Prepaid Assets |
|
-0.15
|
| Change In Payables And Accrued Expense |
|
-0.11
|
| Change In Accrued Expense |
|
-0.39
|
| Change In Payable |
|
0.28
|
| Change In Account Payable |
|
0.28
|
| Investing Cash Flow |
|
-0.69
|
| Cash Flow From Continuing Investing Activities |
|
-0.69
|
| Net PPE Purchase And Sale |
|
-0.69
|
| Purchase Of PPE |
|
-1.13
|
| Sale Of PPE |
|
0.44
|
| Capital Expenditure |
|
-1.13
|
| Financing Cash Flow |
|
70.04
|
| Cash Flow From Continuing Financing Activities |
|
70.04
|
| Net Issuance Payments Of Debt |
|
0.00
|
| Repayment Of Debt |
|
0.00
|
| Long Term Debt Payments |
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
|
| Net Common Stock Issuance |
|
69.92
|
| Proceeds From Stock Option Exercised |
|
0.47
|
| Net Other Financing Charges |
|
-0.36
|
| Changes In Cash |
|
-7.75
|
| Beginning Cash Position |
|
48.38
|
| End Cash Position |
|
40.63
|
| Free Cash Flow |
|
-78.22
|
| Interest Paid Supplemental Data |
|
2.13
|
| Common Stock Issuance |
|
69.92
|
| Issuance Of Capital Stock |
|
69.92
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|